Burning Rock Biotech (BNR) Cash from Operations (2019 - 2026)

Burning Rock Biotech (BNR) has reported Cash from Operations for 8 consecutive years, with 4248000.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash from Operations fell 31.03% year-over-year to 4248000.0; the TTM figure through Mar 2026 stood at 8127000.0 (up 63.25% YoY), while the FY2025 annual figure was 4068000.0, up 67.82% from the prior year.
• Cash from Operations came in at 4248000.0 for Q1 2026 at Burning Rock Biotech, down from 3293000.0 in the prior quarter.
• The five-year high for Cash from Operations was 3293000.0 in Q4 2025, with the low at 22772000.0 in Q1 2022.
• Average Cash from Operations over 5 years is 8212581.19, with a median of 6499000.0 recorded in 2023.
• The largest YoY upside for Cash from Operations was 215.74% in 2024 against a maximum downside of 144.08% in 2024.
• Year by year, Cash from Operations stood at 9519880.29 in 2022, then soared by 76.3% to 2256000.0 in 2023, then jumped by 215.74% to 2611000.0 in 2024, then grew by 26.12% to 3293000.0 in 2025, then slumped by 229.0% to 4248000.0 in 2026.
• According to Business Quant data, Cash from Operations over the past three periods registered 4248000.0, 3293000.0, and 2303000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.